A Phase 3 interventional study of Alpha-1 MP and alpha-1 proteinase inhibitor (human) in Alpha 1-Antitrypsin Deficiency, sponsored by Grifols Therapeutics LLC. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-09.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 14th largest by enrollment, is one of 4 that started in 2006, is one of 7 in phase 3, and was the 3rd registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:
CSL Behring · Sites in Denmark
Ages 18–65
Grifols Therapeutics LLC · Sites in United States, Australia, Canada and 9 more countries
Ages 20–72
By country, each count listing its studies:
alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 7 · Phase 4 6
First in 2003; this study’s year is marked. 4 started in 2006.
This study's enrollment of 24 is below the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 25 interventional studies. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
12 studies in alpha 1-Antitrypsin Deficiency by Grifols: 2 open now, 2 under way, 2 of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 12 studies in alpha 1-Antitrypsin Deficiency by Grifols, this one is the 9th largest by enrollment, is one of 2 that started in 2006, is one of 5 in phase 3, and was the 2nd registered.
Grifols’s alpha 1-Antitrypsin Deficiency studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, from their registry updates:
Among Grifols’s 12 in alpha 1-Antitrypsin Deficiency:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study (ChAMP - Comparability pharmacokinetics of Alpha-1 Modified Process) is to compare the pharmacokinetic, safety and tolerability of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP) and Prolastin in adult Alpha1-antitrypsin deficient patients. Patients will be infused intravenously with study drug on a weekly schedule for 24 weeks.
The objective of this study is to demonstrate the pharmacokinetic comparability of Alpha-1 MP to Prolastin® in subjects with Alpha1-antitrypsin deficiency.
This study is divided into three 8-week treatment sequences including an initial 8-week double-blind treatment period (with one of the 2 study drugs), a second 8-week double-blind treatment period (with the other study drug), and a third 8-week open-label treatment period (with Alpha-1 MP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequential, blinded treatment periods of Alpha-1 MP (experimental), then crossed-over to Prolastin (active comparator), followed by open-label Alpha-1 MP
Drug: Alpha-1 MP
Sequential, blinded treatment periods of Prolastin (active comparator), then crossed-over to Alpha-1 MP (experimental), followed by open-label Alpha-1 MP
Drug: alpha-1 proteinase inhibitor (human)
alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
Also known as: Alpha-1 antitrypsin (AAT), TAL6004
Prolastin
Also known as: Alpha-1 antitrypsin (AAT), BAY x 5747, BAY 10-5233, TAL-05-00007
Alpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7
The primary objective of this study was to demonstrate the pharmacokinetic comparability (geometric least square mean ratio of AUC between the Alpha-1 MP vs. Prolastin®, 90% confidence interval falls within 0.80-1.25, FDA Guidance as being "bioequivalent" between two treatments) of Alpha-1 MP to Prolastin® in subjects with alpha-1-anti-trypsin (AAT) deficiency by comparing AUC from Day 0 to Day 7 of plasma Alpha1-PI measured by the functional activity (potency) assay. AUC from Day 0 to Day 7 was calculated at steady state at the end of the first and second 8-week treatment periods during the 16-week double-blind, crossover phase.
Time frame: Day 0 to Day 7
First-subject-first-dose was on 22 May 2006, Last-subject-last-visit was on 28 Feb 2007. The trial was performed at 6 clinical sites in the United States.
| Milestone | Alpha-1 MP / Prolastin | Prolastin / Alpha-1 MP |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
The primary objective of this study was to demonstrate the pharmacokinetic comparability (geometric least square mean ratio of AUC between the Alpha-1 MP vs. Prolastin®, 90% confidence interval falls within 0.80-1.25, FDA Guidance as being "bioequivalent" between two treatments) of Alpha-1 MP to Prolastin® in subjects with alpha-1-anti-trypsin (AAT) deficiency by comparing AUC from Day 0 to Day 7 of plasma Alpha1-PI measured by the functional activity (potency) assay. AUC from Day 0 to Day 7 was calculated at steady state at the end of the first and second 8-week treatment periods during the 16-week double-blind, crossover phase.
| mg*h/mL | Alpha-1 MP | Prolastin |
|---|---|---|
| Alpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7 | 155.9 (0.97 to 1.09) | 152.4 (0.97 to 1.09) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alpha-1 MP | — | 0/24 (0%) | 3/24 (12.5%) |
| Prolastin | — | 1/24 (4.2%) | 5/24 (20.8%) |
| Event | Alpha-1 MP | Prolastin |
|---|---|---|
| Cervical spinal stenosisMusculoskeletal and connective tissue disorders | 0/24 | 1/24 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/24 | 1/24 |
| Event | Alpha-1 MP | Prolastin |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/24 | 1/24 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/24 | 2/24 |
| HeadacheNervous system disorders | 1/24 | 2/24 |
| Age, Categorical(Participants) | Alpha-1 MP / Prolastin | Prolastin / Alpha-1 MP | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 10 | 20 |
| >=65 years | 2 | 2 | 4 |
| Age, Continuous(years) | Alpha-1 MP / Prolastin | Prolastin / Alpha-1 MP | Total |
|---|---|---|---|
| Mean | 58.4 ± 6.86 | 57.0 ± 9.33 | 57.7 ± 8.04 |
| Sex: Female, Male(Participants) | Alpha-1 MP / Prolastin | Prolastin / Alpha-1 MP | Total |
|---|---|---|---|
| Female | 6 | 8 | 14 |
| Male | 6 | 4 | 10 |
| Region of Enrollment(participants) | Alpha-1 MP / Prolastin | Prolastin / Alpha-1 MP | Total |
|---|---|---|---|
| United States | 12 | 12 | 24 |
The record gives a start of May 2006, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 7 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency →